Treatment of PG is currently limited to immune-suppressing drugs and antibiotics to treat complicating infections, and, in ...

The only available treatment for a patient with coeliac disease is a strict gluten-free diet, which is often not enough on ...

Drug discovery, and science in general, are fields built on data. Foundation models bring new capabilities by integrating ...

Molbreevi – a new inhaled formulation of the well-established and off-patent white blood cell stimulator molgramostim – is ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...

In another signal of downgraded support for COVID-19 vaccination programmes under the Trump administration, the CDC has ...

Recent history should have the pharmaceutical industry questioning some of its fundamental assumptions. The COVID-19 pandemic led to skyrocketing demand for some products while simultaneously ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a ...

Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US ...

The Chinese biotech industry has grown rapidly to become a major hub of research. However, as US-China trade relations continue to deteriorate, Ben Hargreaves asks whether this could stunt ...